Fas antigen (CD95) in pure erythroid cell line AS-E2 is induced by interferon-γ and tumor necrosis factor-α and potentiates apoptotic death

Experimental Hematology

Volumn 27, Issue 3, 1999, Pages 433-440

  Tsushima, Hideki ^a   Imaizumi, Yoshitaka ^a   Imanishi, Daisuke ^a   Fuchigami, Kengo ^a   Tomonaga, Masao ^a  

^a Nagasaki University   (Japan)

Author keywords

Apoptosis; AS E2; Erythroid progenitors; Fas; Tumor necrosis factor Interferon

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; DNA CLEAVAGE; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; ASPARTIC ACID; CASPASE 1; CASPASE 3; CASPASES; CELL DIVISION; DNA FRAGMENTATION; ENZYME INHIBITORS; ERYTHROID PROGENITOR CELLS; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; OLIGOPEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033017043     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(98)00028-9     Document Type: Article

References (50)

1. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 81:1993;2844.
2. Zoumbos N.C., Gascon P., Djeu J.Y., Young N.S. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A. 82:1985;188.
3. Hintenberger W., Adolf G., Bettelheim P. Lymphokine overproduction in severe aplastic anemia is not related to blood transfusions. Blood. 74:1989;2713.
4. Katevas P., Maciejewski J.P., Sorrentino B., Young N.S. Increased expression of TNF-beta in patients with aplastic anemia. Blood. 82(suppl.):1993;345a.
5. Rosseli F., Sanceau J., Gluckman E., Wietzerbin J., Moustacchi E. Abnormal lymphokine production. a novel feature of the genetic disease Fanconi anemia Blood. 83:1994;1216.
6. Seipelt G., Ganser A., Duranceyk H., Maurer A., Ottman O.G., Holzer D. Induction of TNF-alpha in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol. 84:1995;749.
7. Verhoef G.E., Schouwer P., Ceuppens J.L., Van Damme J.O., Goossens W., Boogaerts M.A. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 6:1992;1268.
8. Iwai K., Miyazaki T., Takizawa T., Konno A., Ohta K., Yachie A., Seki H., Tanigushi N. Differential expression of Bcl-2 and susceptibility to anti-Fas mediated cell death in peripheral blood lymphocytes, monocytes and neutrophils. Blood. 84:1994;1201.
9. Matsuo K., Schleimer R.P., Saito H., Likura Y., Bochner B.S. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood. 86:1995;1437.
10. Maciejewski J.P., Selleri C., Sato T., Anderson S., Young N.S. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. Br J Haematol. 91:1995;245.
11. Bouscary D., De Vos J., Guesnu M., Jondeau K., Viguier F., Melle J., Picard F., Dreyfus F., Fontenay-Roupie M. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 11:1997;839.
12. Lepelly P., Campergue L., Grardel N., Preudhomme C., Cosson A., Fenaux P. Is apoptosis a massive precess in myelodysplastic syndromes? Br J Haematol. 95:1996;368.
13. Johnson R.A., Waddelow T.A., Caro J., Oliff A., Roodman G.D. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mouse. Blood. 74:1989;130.
14. Broxmeyer H.E., Lu L., Platzer E., Feit C., Juliano L., Rubin B.Y. Comparative analysis of the influences of γ, α and β interferons on human multipotential (CFU-GEMM), erythroid (BFU-E), and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol. 131:1983;1300.
15. Roodman G.B., Bird A., Hutzler D., Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors. effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell line K562, HL60, and HEL cells Exp Hematol. 15:1987;928.
16. Johnsos R.A., Waddelow T.A., Caro J., Oliff A., Roodman G.D. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood. 74:1989;130.
17. Means R.T., Krantz S.B. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest. 91:1993;416.
18. Means R.T. Jr., Dessypris E.N., Krantz S.B. Inhibition on human colony-forming unit erythroid by tumor necrosis factor requires accessory cells. J Clin Invest. 86:1990;538.
19. Rusten L.V., Jacobsen S.E.W. Tumor necrosis factor (TNF-α) directly inhibits human erythropoiesis in vitro. role of p55 and p75 TNF receptors Blood. 85:1995;989.
20. Broxmeyer H.E., Willoams D.E., Lu L. The suppressive influences of human tumor necrosis factors on bone marrow progenitor cells from normal donors and from patients with leukemia. synergism of tumor necrosis factor and interferon-γ J Immunol. 136:1986;4487.
21. Murase T., Hotta T., Saito H., Ohno R. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood. 69:1987;467.
22. Murphy M., Perussia B., Trinchieri G. Effects of recombinant tumor necrosis factor, lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic precursor cells. Exp Hematol. 16:1988;131.
23. Rigby W.G.C., Ball E.D., Guyre P.M., Fanger M.W. The effects of recombinant DNA-derived interferons on the growth of myeloid progenitor cells. Blood. 65:1985;858.
24. Caux C., Favre C., Saeland S., Duvert V., Durand I., Mannoni P., Banchereau J. Potentiation of early hematopoiesis by tumor necrosis factor-α is followed by inhibition of granulopoietic differentiation and proliferation. Blood. 78:1991;635.
25. + human bone marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 85:1995;3183.
26. Nagafuji K., Shibuya T., Harada M., Mizuno S., Takenaka K., Miyamoto T., Okamura T., Gondo H., Niho Y. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood. 86:1995;883.
27. Henkart P.A. ICE family proteases. mediators of all apoptotic cell death? Immunity. 4:1996;195.
28. Miyazaki Y., Kuriyama K., Higuchi M., Tsushima H., Sohda H., Imai N., Saito M., Kondo T., Tomonaga M. Establishment and characterization of a new erythropoietin dependent acute myeloid leukemia cell line, AS-E2. Leukemia. 11:1997;1941.
29. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju S.M.et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37.
30. Thornberry N.A., Bull H.G., Calaycay J.R., Chapman K.T., Howard A.D., Kostura M.J., Miller D.K., Molineaux S.M., Weidner J.R., Aunins J. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 356:1992;768.
31. Dolle R.E., Hoyer D., Prasad C.V., Schmidt S.J., Helazek C.T., Miller R.E., Ator M.A. P1 asparatate-based alpha-((2,6-dichlorobenzoyl)oxy) methyl ketones as potent time-dependent inhibitors of interleukin-1 beta-converting enzyme. J Med Chem. 37:1994;563.
32. Mashima T., Naito M., Kataoka S., Kawai H., Tsuruo T. Aspartate-based inhibitor of interleukin-1β-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells. Biochem Boiphys Res Commun. 209:1995;907.
33. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:1992;3887.
34. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack. Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J Exp Med. 184:1996;1075.
35. Barbu V., Dautry F. Northern blot normalization with a 28S rRNA oligonucleotide probe. Nucleic Acids Res. 17:1989;7115.
36. Alnemri E.S., Fernandez-Alnemri T., Litwack G. Cloning and expression of four novel isoforms of human interleukin 1β converting enzyme with different apoptotic activities. J Biol Chem. 270:1995;4312.
37. + cells. Br J Haematol. 97:1997;356.
38. Akbar A.N., Borthwick N.J., Wickremasinghe R.G., Panayiotidis P., Pilling D., Bofill M., Krajewski S., Reed J.C., Salmon M. Interleukin-2 receptor common g-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal. selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xs) gene expression Eur J Immunol. 26:1996;294.
39. Dai C.-H., Price J.O., Brunner T., Krantz S.B. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon γ to produce erythroid cell apoptosis. Blood. 91:1998;1235.
40. Erhardt P., Cooper G.M. Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-xL. J Biol Chem. 271:1996;17601.
41. Gregoli P.A., Bondurant M.C. The roles of Bcl-xL and apopain in the control of erythropoiesis by erythropoietin. Blood. 90:1997;630.
42. Schlegel J., Peters I., Orrenius S., Miller D.K., Thornberry N.A., Yamin T.T., Nicholson D.W. CPP32/apopain is a key interleukin 1 beta converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem. 271:1996;1841.
43. Hasegawa J., Kamada S., Kamiike W., Shimizu S., Imazu T., Matsuda H., Tsujimoto Y. Involvement of CPP32/Yama (-like) protease in Fas-mediated apoptosis. Cancer Res. 56:1996;1713.
44. Darmon A.J., Ley T.J., Nicholson D.W., Bleackley R.C. Cleavage of CPP32 by granzyme B represents a critical role for granzyme B in induction of target cell DNA fragmentation. J Biol Chem. 271:1996;21709.
45. Martin S.J., Amarante-Mendes G.P., Shi L., Chuang T.H., Casiano C.A., O'Brien G.A., Fitzgerald P., Tan E.M., Bokoch G.M., Greenberg A.H., Green D.R. The cytotoxic cell protease granzyme B initiates apoptosis in a cell free system by proteolytic processing and activation of the ICE/CED-3 family protease, CPP-32, via novel two-step mechanism. EMBO J. 15:1996;2407.
46. Datta R., Kojima H., Banach D., Bump N.J., Talanian R.V., Alnemri E.S., Weichselbaum R.R., Wong W.W., Kufe D.W. Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. J Biol Chem. 272:1997;1965.
47. Datta R., Banach D., Kojima H., Talanian R.V., Alnemri E.S., Wong W.W., Kufe D.W. Activation of the CPP-32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood. 88:1996;1936.
48. Jacobson M.D., Weil M., Raff M.C. Role of Ced-3/ICE-family of proteases in staurosporine-induced programmed cell death. J Cell Biol. 133:1996;1041.
49. Tsushima H., Urata Y., Miyazaki Y., Fuchigami K., Kuriyama K., Kondo T., Tomonaga M. Human erythropoietin receptor increases GATA-2 and Bcl-xL by a protein kinase C-dependent pathway in human erythropoietin-dependent cell line AS-E2. Cell Growth Differ. 8:1997;1317.
50. Tamura T., Ueda S., Yoshida M., Matsuzaki M., Mohri H., Okubo T. Interferon-g induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun. 229:1996;21.